
Echidna mothers change their pouch microbiome to protect tiny ‘pink jelly bean' puggles, new research finds
These first few weeks are critical for puggles. At this early developmental stage, they are tiny – roughly the size of a 5-cent coin – and vulnerable.
'They can't see and they don't have a functional immune system,' said Isabella Wilson, lead author of the study published in FEMS Microbiology Ecology.
Echidnas lay their eggs into a temporary pouch, which they create by contracting their abdominal muscles. After about 10 days, puggles hatch from their eggs looking like, in Wilson's words, 'little pink jelly beans'.
During lactation, probiotic bacteria in the echidna's pouch increases, which the University of Adelaide researchers suggested offers protection to puggles and their developing immune systems.
The reproductive biology of the echidna is unique in many respects, Wilson said.
Monotremes – echidnas and platypus – share a lot of 'weird features', she said. As well as laying eggs, they lack nipples. So instead of suckling, puggles rub their beaks against a part of the pseudo-pouch called the milk patch, causing milk to come out of the mother's skin.
Sign up for Guardian Australia's breaking news email
This milk, which is sometimes pink, has barely any lactose compared to that of most other animals.
'The young hang out there [in the pseudo-pouch] for a few months, drink up a lot of milk,' Wilson said.
'Then, when they start to grow spines, they get turfed out of the pouch into the nursery burrow – where they continue to feed off mum for about 200 days.'
An echidna's pouch is only temporary – it is there while a puggle is inside. Healesville Sanctuary echidna keeper Craig McQueen, who was not involved in the research, agreed puggles generally stayed there for six to seven weeks, until their spines became 'too prickly' for mum.
Sign up to Breaking News Australia
Get the most important news as it breaks
after newsletter promotion
He said echidnas were curious animals that invested a lot of time into raising their young.
When they hatch out of their grape-sized egg, puggles are furless, blind and 'basically looked like they shouldn't have been born yet', he said – which is why they need the 'extra developmental time' in the pouch.
The paper explains that the reproductive microbiome, 'which includes vaginal, milk, and mammary microbiota, is increasingly being recognised for its contributions to infant health'. And in monotremes and marsupials, this extends to the pouch.
Researchers analysed bacteria present on swabs from both captive animals at Taronga Zoo and wild echidnas on Kangaroo Island. They found that the pouch's microbiome underwent significant changes during lactation, with an increase in lactic acid bacteria typically thought of as probiotic.
They found no major difference between the microbiomes of the zoo-managed and wild animals. Wilson said this suggested that milk, rather than any external factors, is the primary element shaping the pouch environment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
an hour ago
- Reuters
CSL to axe up to 3,000 employees and spin off vaccine arm; shares tumble
Aug 19 (Reuters) - Australian biotech CSL, ( opens new tab the country's fourth-largest company, said on Tuesday it would spin off its vaccine division and shed about 3,000 employees as it reels from "unprecedented volatility," sending its shares tumbling. The company, which makes most of its profit selling blood plasma treatments for rare illnesses, met analyst forecasts with a 14% increase in annual profit but said it was carving off its vaccine unit where profit dipped due to what its CEO called "highly irrational" softness in the U.S. For its main earner, collecting blood from the public mostly in the U.S. and converting it to medical treatments, CSL reported slower-than-expected profit growth. The company said it closed 22 collection centres this month and would "consolidate" its research and development, all culminating in a reduction of up to 15% of workers outside its U.S. plasma unit. "Our business has grown this year despite an unprecedented level of challenge and volatility in our external operating environment," CEO Paul McKenzie said in a statement. The company didn't provide a valuation for the demerger, which it expects to complete in early 2026, but McKenzie said the cost-cutting would "further reshape and simplify the business (and) provide a platform to renew CSL's focus on our core strengths." On a call with analysts, McKenzie made only a passing reference to hefty tariffs on pharmaceutical imports threatened by U.S. President Donald Trump, saying he didn't believe they would apply to CSL because its core ingredient was sourced inside the U.S. For the company's non-blood plasma products, "the active pharmaceutical ingredient is sourced in the U.S. as well", McKenzie added. "For the other parts of the organisation, we will look at our supply chain and where the products come from". CSL shares were down 15% by afternoon and were headed toward their worst session, dragging the broader index (.AXJO), opens new tab down 0.7%, as analysts fretted about the implications of the restructure. "Cutting back staff is normally a positive thing but I suspect that it will have an impact on earnings growth and that's what the market seems to be focused on at the moment," said Craig Sidney, a senior investment advisor at Shaw and Partners. The company's future earnings guidance, which was just short of previous expectations, may also hurt the stock, Craig Wong-Pa, analyst at RBC Capital Markets, said. The former government laboratory forecast underlying annual earnings between $3.45 billion and $3.55 billion in the 2026 financial year, just short of a Visible Alpha consensus of $3.56 billion. CSL said the restructure would save it up to $550 million a year within three years, although it would incur a one-off pre-tax charge of up to $770 million in the current financial year. The company said it would also buy back A$750 million ($486.68 million) of shares this financial year. It declared a final dividend of $1.62 per share, up from $1.45 per share declared a year ago. ($1 = 1.5411 Australian dollars)


The Guardian
2 hours ago
- The Guardian
Why can't the world get its act together on plastics?
Clips: Fox News, BBC, 7News Australia, France 24, DW News, CNA Support the Guardian:


Reuters
4 hours ago
- Reuters
CSL to lay off up to 15% of workforce and spin off flu vaccine arm; shares tumble
Aug 19 (Reuters) - Australian biotech firm CSL ( opens new tab said on Tuesday it would spin off its influenza vaccine division and would cut up to 15% of its workforce as part of a strategic overhaul, sending its shares tumbling 11%. It is also targeting annualised savings of up to $550 million over the next three years and plans to book a one-off pre-tax charge of up to $770 million in the current financial year. "The transformational initiatives we are announcing today will further reshape and simplify the business, provide a platform to renew CSL's focus on our core strengths," CEO Paul McKenzie said in a statement. The strategic overhaul was announced in tandem with earnings, with CSL reporting a 14% rise in underlying profit for the year ended June to $3.3 billion on a constant currency basis, driven by a strong performance from its blood plasma business, CSL Behring. It aims to spin off the flu vaccine unit, CSL Seqirus, into a separately listed entity in Australia by next June, as lower U.S. immunisation rates and potential U.S. tariffs on pharmaceuticals cloud the division's outlook. Craig Sidney, a senior investment advisor at Shaw and Partners, said the spin-off "could actually unlock some value and that may well be positive". But CSL, which employs some 29,900 people, saw its stock tumble to its lowest in five weeks, making it the worst performer in the ASX200 benchmark index (.AXJO), opens new tab, which traded 0.6% lower. "Cutting back staff is normally a positive thing, but I suspect that it will have an impact on earnings growth and that's what the market seems to be focused on at the moment," Sidney said. CSL also said it will resume its share buyback program, starting with A$750 million ($486 million) this financial year. CSL Behring's fiscal 2025 revenue grew 6% to $11.16 billion, with demand for its core plasma therapies expected to remain robust in 2026. That underpinned CSL's forecast of underlying annual earnings of between $3.45 billion and $3.55 billion on a constant currency basis, though the midpoint of the range fell short of the Visible Alpha consensus of $3.56 billion. CSL, founded more than a century ago as a government laboratory, declared a final dividend of $1.62 per share, up from $1.45 per share declared a year ago. ($1 = 1.5415 Australian dollars)